Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04634916 · ClinicalTrials.gov registry record · NA

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

A NA study of End Stage Renal Disease and Arteriovenous Fistula, sponsored by C. R. Bard.

Recruiting
Registry status
NA
Development phase
280
Enrollment target
17
Study locations

NCT04634916 is a NA study of End Stage Renal Disease and Arteriovenous Fistula that is actively recruiting participants, run by C. R. Bard. The registered enrollment target is 280 participants, below the 830-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (66% lower). The trial reports 17 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04634916, a NA study of End Stage Renal Disease and Arteriovenous Fistula, is actively recruiting participants, sponsored by C. R. Bard.

RECRUITING
Registry status
NA
Development phase
280 participants
Enrollment target
17
Study locations

Study Summary

A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.

Conditions Studied

End Stage Renal Disease Arteriovenous Fistula Kidney Disease, End-Stage

Interventions

  • DEVICE EndoAVF Creation

Study Locations (17)

Florida

  • First Coast Cardiovascular Institute Pa - Jacksonville
  • Radiology and Imaging Specialists - Lakeland
  • Vascular and Spine Institute Inc - Miami

Massachusetts

  • Kidney Care and Transplant Services of NE - Springfield
  • Kidney Care & Transplant Services of New England - West Springfield
  • UMass Chan School of Medicine - Worcester

California

  • California Institute of Renal Research - La Jolla
  • San Francisco Vein & Vascular - San Francisco

Tennessee

  • Vascular Institute of Chattanooga - Chattanooga
  • Bluff City Vascular - Memphis

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • Houston Methodist - Houston

New York

  • Albany Medical Center - Albany

North Carolina

  • NC Nephrology - Raleigh

Ohio

  • ProMedica Toledo Hospital - Toledo

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2021-03-26
Est. Completion 2027-09
Phase NA

Sponsor

C. R. Bard

75 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04634916

The ClinicalTrials.gov registry entry for NCT04634916 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 830-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (66% lower). The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which EndoAVF Creation is the first listed.

NCT04634916 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Florida, Massachusetts, California.

Frequently Asked Questions

What is clinical trial NCT04634916 about?

NCT04634916 is a clinical study titled "Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System". A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.

What is the current status of trial NCT04634916?

This trial is currently recruiting. It is a NA study. The enrollment target is 280 participants. The study started on 2021-03-26. Estimated completion is 2027-09.

What conditions does trial NCT04634916 study?

This clinical trial studies the following conditions: End Stage Renal Disease, Arteriovenous Fistula, Kidney Disease, End-Stage.

What interventions are being tested in trial NCT04634916?

The interventions under investigation include: EndoAVF Creation (DEVICE).

Who is sponsoring clinical trial NCT04634916?

This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04634916 being conducted?

This trial has 17 study locations across California, Florida, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

End Stage Renal Disease

All registered trials for this condition

Arteriovenous Fistula

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.